Revance to Participate in the Needham 22nd Annual Healthcare Conference
April 05 2023 - 8:00AM
Business Wire
Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that
the company will participate in the 22nd Annual Needham Virtual
Healthcare Conference, taking place April 17 – 20, 2023. Chief
Financial Officer, Tobin Schilke, is scheduled to participate in a
fireside chat on Tuesday, April 18, at 12:45 P.M. ET.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company's
website at www.revance.com. The webcast replay will be available
after the conclusion of the live presentation for approximately 90
days.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
elevate patient and physician experiences. Revance’s aesthetics
portfolio of expertly created products and services, including
DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA®
Collection of dermal fillers, and OPUL®, the first-of-its-kind
Relational Commerce platform for aesthetic practices, deliver a
differentiated and exclusive offering for the company’s elite
practice partners and their consumers. Revance has also partnered
with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for
injection, which will compete in the existing short-acting
neuromodulator marketplace. Revance’s therapeutics pipeline is
currently focused on muscle movement disorders including evaluating
DAXXIFY® in two debilitating conditions, cervical dystonia and
upper limb spasticity.
Revance is headquartered in Nashville, Tennessee, with
additional office locations in Newark, Pleasanton and Irvine,
California. Learn more at www.Revance.com,
www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on
LinkedIn.
“Revance” and the Revance logo, DAXXIFY®, and OPUL® are
registered trademarks of Revance Therapeutics, Inc. Resilient
Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230405005155/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
510-279-6886 jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476
sfahy@revance.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jul 2023 to Jul 2024